SCHEMBL10189261

SCHEMBL10189261

COc1ccc(-c2csnc2-c2cc(C)c3c(c2)OCO3)c(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
APP P05067 1/20 0.38
ACHE P22303 1/20 0.38
LMNA P02545 3/20 0.37
ALDH1A1 P00352 3/20 0.37
ALOX15 P16050 2/20 0.37
HTT P42858 2/20 0.37
ALOX12 P18054 2/20 0.37
CLK1 P49759 1/20 0.37
HPGD P15428 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617962 0.90 MAPT (0.45) MAPTAPPACHELMNAALDH1A1
SCHEMBL10189271 0.89 ACHE (0.37) MAPTAPPACHELMNAALDH1A1
SCHEMBL10189273 0.85 ACHE (0.35) MAPTAPPACHELMNAALDH1A1
SCHEMBL10189264 0.82 CASP3 (0.41) MAPTAPPACHELMNAALDH1A1
SCHEMBL10189278 0.82 UGT1A1 (0.41) MAPTLMNAALDH1A1HTTHPGD
SCHEMBL12339063 0.82 MAPT (0.41) MAPTAPPACHELMNAALDH1A1
SCHEMBL10189263 0.80 CYP2A6 (0.45) APPACHE
SCHEMBL10242362 0.78 ALDH1A1 (0.44) MAPTAPPACHELMNAALDH1A1
SCHEMBL10189765 0.78 ALOX12 (0.45) MAPTAPPACHELMNAALDH1A1
SCHEMBL10189279 0.78 GRB2 (0.32) MAPTLMNAALDH1A1HTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 MAPT 95/4885APP 4674/4885ACHE 4837/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 MAPT 95/4885APP 4674/4885ACHE 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.